Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrustTSC phase 3 adjunctive ganaxolone in TSC-associated epilepsy
MOH_2022-11-16_012025Phase 3Active, not recruiting
- Sponsor
- Marinus Pharmaceuticals
- Start
- Nov 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy and tuberous sclerosis complex (TSC) comparing Standard therapy + ZTALMY with Standard therapy + placebo (2 arms). Primary endpoints: Change from baseline in countable seizure frequency during the double-blind phase and Safety of ganaxolone. Started Nov 2022; status: active, not recruiting.
02
Drugs
ganaxolone
03
Conditions
epilepsytuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on MOH_2022-11-16_012025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-16_012025.